EsoCap announces publication of comprehensive Phase II results demonstrating ESO-101’s effectiveness in eosinophilic esophagitis
17. Dezember 2024 05:00 ET
|
EsoCap AG
Detailed results of the ACESO Phase II study published in the peer-reviewed medical journal Alimentary Pharmacology & TherapeuticsESO-101 leverages EsoCap’s unique drug delivery technology to...
EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
20. Mai 2022 05:00 ET
|
EsoCap AG
Patients with eosinophilic esophagitis (EoE) suffer from severe symptoms including swallowing disorders, food impaction, vomiting, and heartburnEsoCap is currently conducting a randomized,...
EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus
10. Januar 2022 05:32 ET
|
EsoCap AG
Licensing deal grants EsoCap exclusive access to Upadia’s monoclonal antibodies for a local therapy for Barrett’s esophagusBarrett’s esophagus, a disease of the esophagus with high unmet medical need,...
EsoCap secures new funding
18. November 2021 08:30 ET
|
EsoCap AG
EsoCap successfully closes a private financing round, with investments from existing and new investorsThe new funding was facilitated by EsoCap benefitting from a unique programme implemented by the...